Affimed

#WorldCancerResearchDay is September 24, a day to raise awareness about the importance of innovative research in the fight against cancer worldwide.  At Affimed, our research is focused on harnessing the immense power of the innate immune system to combat cancer by targeting and activating NK cells and macrophages with our innate cell engagers (ICE®). Our ongoing research includes studying acimtamig (AFM13) and AFM28 for their potential in treating certain blood cancers and AFM24 which we are studying for non-small cell lung cancer.  Find out more about our research at www.affimed.com #WorldCancerResearchDay #InnateImmunity #ImmunoOncology #AFMD #Immunotherapy #WhyWeFightCancer  

Affimed Chief Executive Officer, Shawn M. Leland, PharmD, RPh, will participate in a fireside chat at the Cantor Global Healthcare Conference 2024 on Tuesday, September 17, 2024, at 8:00 a.m. Eastern Daylight Time / 14:00 Central European Time. A live webcast of the presentation will be accessible on Affimed’s website at https://bit.ly/43ACvls A replay of the call will be archived on Affimed’s website for 30 days after the call.    #AFMD #ImmunoOncology #InnateImmunity #WhtWeFightCancer

World Lymphoma Awareness Day, observed on September 15th each year during Blood Cancer Awareness Month, aims to increase global awareness of lymphoma. Lymphoma is a group of blood cancers affecting the lymphatic system and is the most common form of blood cancer worldwide with over 635,000 new cases and 270,000 deaths estimated in 2022*. World Lymphoma Awareness Day serves as a vital platform to raise awareness about lymphoma, educate the public on its signs and symptoms, and support ongoing research for better treatments. At Affimed, we are committed to harnessing the power of the innate immune system to combat cancer. Our research includes the development of innate cell engagers (ICE®) like acimtamig (AFM13), which is currently under investigation for its potential in treating certain CD30+ blood cancers. We are committed to advancing novel therapies for lymphoma, especially for patients who have limited treatment options.   #BloodCancerAwarenessMonth #WhyWeFightCancer #InnateImmunity #AFMD #Immunotherapy #WorldLymphomiaDay * GLOBOCAN cancer statistics 2022: estimates of incidence and mortality worldwide for 36 cancers in 185 countries

"Congratulations to our colleagues for securing the first place in the yearly charity regatta “Rudern Gegen Krebs” (“Rowing Against Cancer”)!  We are incredibly proud of their dedication and contribution to this wonderful event, hosted in front of the stunning backdrop of Heidelberg."    This row is a yearly event where patients, medical professionals, and rowers of all skill levels come together to raise money and support medically supervised sports and exercise therapies for patients with cancer. It takes place in multiple locations throughout Germany in cooperation with local rowing clubs and oncological treatment facilities. The team at Affimed, some captured in the photos from the event, always have a great time supporting the row and helping raise money in support cancer patients. See you again next year!     #ruderngegenkrebs #affimed #innateimmunity #cancertherapy #WhyWeFightCancer  

On September 5, 2024, at 8:30 a.m. EDT / 14:30 CET, we discuss our Q2 2024 financial results and provide a corporate update in a conference call. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://bit.ly/43ACvls    #AFMD #InnateImmunity #WhyWeFightCancer

We are thrilled to announce Shawn Leland, Pharm D, RPh is Affimed’s new CEO. Shawn has a proven track record in advancing cutting-edge oncology assets, securing significant capital, and negotiating global licensing agreements which will serve him well as he leads Affimed and its vision to stop cancer from ever derailing patients’ lives Read more here: https://bit.ly/3Tdpv2k #AFMD #InnateImunity #WhyWeFightCancer

September is Blood Cancer Awareness Month – an important time to raise awareness of the different types of blood cancers, their symptoms, and the need for continued research to find effective treatment options. At Affimed we are focused on leveraging the immense power of the innate immune system to fight cancer with our ICE® molecules. We are committed to developing novel therapies for different blood cancers including certain types of lymphoma and leukemia where patients often have limited options. #BloodCancerAwarenessMonth #WhyWeFightCancer #InnateImmunity #AFMD #Immunotherapy

August 1st is #WorldLungCancerDay – started in 2012 as an effort to raise awareness of lung cancer, one of the most common and deadly cancers across the world, and to educate people about its risks, prevention, and symptoms in order to help increase early detection. At Affimed, we are developing novel therapies for hard-to-treat cancers including advanced non-small cell lung cancer (NSCLC) where patients too often have limited options. We are united in our shared vision of leveraging the innate immune system to create a future where cancer no longer derails the lives of patients and their loved ones. #AFM24 #InnateImmunity #ImmunoOncology #WhyWeFightCancer

We are #AffimedProud of all of our colleagues who joined more than 5,000 runners worldwide in the 13th National Center for Tumor Diseases (NCT) Heidelberg Virtual Run this July to help raise money for #CancerResearch. #nctrun #nctlauf #WhyWeFightCancer #TeamAffimed

Yesterday, Affimed reported first quarter 2024 financial results and provided a business update including new data from ongoing clinical trials with our ICE® acimtamig (AFM13) and AFM28. Read the full press release here: https://bit.ly/3Xkz820 #WhyWeFightCancer #AFMD #innateimmunity